Vectory Raises €129 Million ($138 Million) Series A Financing To Advance Vectorized Antibody Programs In Neurodegenerative Diseases
Amount Raised
€129 Million
Round Type
Series A
Investors
Description
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the close of a €129 million ($138 million) Series A financing to advance its vectorized antibody programs in neurodegenerative diseases. The round was co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund.
Quick answer
VectorY raised €129 Million in a Series A round, dated November 13, 2023. Investors: Bio Generation Ventures, Forbion Ventures, ALS Investment Fund, Insight Partners, Nj Usa, Rahway, MRL Ventures Fund and Forbion Growth Opportunities Fund.
- How much did VectorY raise?
- VectorY raised €129 Million in a Series A round on November 13, 2023.
- Who invested in VectorY?
- Bio Generation Ventures, Forbion Ventures, ALS Investment Fund, Insight Partners, Nj Usa, Rahway, MRL Ventures Fund and Forbion Growth Opportunities Fund are named as investors in this round.
- What does VectorY do?
- VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
- Where is VectorY based and how big is it?
- Fundz records about 82 employees.
- Who are the decision-makers at VectorY?
- Fundz holds 1 contact at VectorY. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as VectorY that raised within 45 days of this round, from Fundz verified event records.
- Alpha Cognition raised $1.8M (Seed) on December 22, 2023.
- Cadenza Bio raised an undisclosed amount (Funding Round) on December 20, 2023.
- Sudo Biosciences raised $116M (Series B) on December 20, 2023.
- Sudo Biosciences raised $53M on December 15, 2023.
- Cadenza Bio raised $2.4M (Seed) on December 14, 2023.
- Bicara Therapeutics raised $165M (Series C) on December 12, 2023.
Who to call at VectorY, and when
A new round usually means VectorY is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day VectorY raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at VectorY, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at VectorY. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment VectorY raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansVectorY raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.